School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Kiniksa Pharmaceuticals International, plc KNSA

Healthcare · Drug Manufacturers - Specialty & Generic

$79.78last close 2026-10-09 · market cap $6.14B · delayed data

Trailing returns

1M+1.60%
3M+22.03%
6M+68.56%
1Y+109.34%
5Y+612.96%

Basis: Adjusted daily closes.

What it does

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.

Open KNSA in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies